The guidance.

The guidance, ‘non-proprietary Naming of Biologic Products,’ would designate unique and separate, nonproprietary names for originator biologic products, related biological items, and biosimilar products. ‘The ACR commends the FDA's proposal to require distinctive titles for biosimilar drugs and primary biologics,’ said Douglas White, MD, Chair of the ACR's Committee on Rheumatologic Care . ‘Distinctive names will allow for higher transparency in substitution and notification, making it clear to all parties involved – pharmacists, providers and individuals – which drug the patient is receiving.’ Related StoriesNo progression in joint damage in 84 percent of psoriatic arthritis patientsHSS experts help identify lupus sufferers at increased risk of problem pregnanciesResistance strength training reduces pain, raises function in people who have hand OAThe ACR previously issued a position statement calling on the FDA to enforce specific brands for biosimilars, and has spoken with FDA officials and submitted comment letters expressing its worries for patient basic safety in instances where biosimilars are substituted without proper patient and doctor notification.

These sobering figures highlight the need for not only conducting further research into coronary disease but also making sure this research is carried out globally.’.. ACRO releases statement on World Heart Day The Association of Clinical Study Organizations , which represents the global leaders in clinical outsourcing, released the following statement in acknowledgement of World Heart Day today. ‘Last year, ACRO member companies conducted nearly 600 clinical trials of brand-new treatments and medications for coronary disease involving 230, 000 patients all over the world,’ stated Doug Peddicord, PhD, Executive Director. ‘Based on the World Heart Association, 17.1 million people die each full year from cardiovascular disease, 80 % of whom are in developing countries.